Evidence map›Paper›PMID 29381456›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2018

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Daniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, Katherine Sunderland, Tilman Todenhöfer, Berhard J Eigl, Daygen Finch, Lyly Le, Andrew Atwell, Bruce Keith and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Daniel Joseph KhalafDepartment of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
Claudia M AvilésDepartment of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
Arun A AzadDepartment of Medicine, Monash University, Clayton, Australia.
Katherine SunderlandDepartment of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
Tilman TodenhöferVancouver Prostate Centre, Vancouver, BC, Canada.
Berhard J EiglDepartment of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
Daygen FinchDepartment of Medical Oncology, BC Cancer Agency - Centre for the Southern Interior, Kelowna, BC, Canada.
Lyly LeDepartment of Medical Oncology, BC Cancer Agency - Fraser Valley Centre, Surrey, BC, Canada.
Andrew AtwellDepartment of Medical Oncology, BC Cancer Agency - Vancouver Island Centre, Victoria, BC, Canada.
Bruce KeithDepartment of Medical Oncology, BC Cancer Agency - Abbotsford Centre, Abbotsford, BC, Canada.
Christian KollmannsbergerDepartment of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
Kim N ChiDepartment of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
BC Cancer Agency · CAMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecently, a prognostic index including six risk factors (RFs) (unfavourable Eastern Cooperative Oncology Group performance status [ECOG PS], presence of liver metastases, short response to luteinizing hormone-releasing hormone [LHRH] agonists/antagonists, low albumin, increased alkaline phosphatase [ALP] and lactate dehydrogenase [LDH]) was developed from the COU-AA-301 trial in post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate. Our primary objective was to evaluate this model in a cohort of chemotherapy-naive mCRPC patients receiving abiraterone.

methodsWe identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ

resultsPatients were classified into good (0-1 RFs), intermediate (2-3 RFs), and poor (4-6 RFs) prognostic groups (33%, 52%, and 15%, respectively). For good-, intermediate-, and poor-risk patients, PSA RR (≥50% decline) was 60% vs. 42% vs. 40% (p=0.05); median time to PSA progression was 7.3 vs. 5.3 vs. 5.0 months (p=0.02); and median OS was 29.4 vs. 13.8 vs. 8.7 months (p<0.0001).

conclusionsThe six-factor prognostic index model stratifies clinical outcomes in chemotherapy-naive mCRPC patients treated with abiraterone. Identifying patients at risk of poor outcome is important for informing clinical practice and clinical trial design.

Identifiers

PMID29381456
PMCPMC5937410
OpenAlexW2772156557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.